Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction

Launched by HARBIN MEDICAL UNIVERSITY · Jun 2, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating the potential benefits of a medication called dexmedetomidine for patients experiencing a type of heart attack known as ST-segment elevation myocardial infarction (STEMI). The study aims to see if this medication can help reduce the size of heart damage during a procedure called primary percutaneous coronary intervention (pPCI), which is done to open blocked arteries in the heart. Participants will be randomly assigned to receive either dexmedetomidine or a placebo (a saline solution that looks the same but has no active medication) during their treatment.

To be eligible for this trial, participants must be between 18 and 75 years old and have been diagnosed with anterior STEMI within six hours of feeling chest pain. They must also be able to sign a consent form agreeing to participate. Throughout the study, participants can expect to receive the assigned treatment during their procedure and will undergo imaging tests five days later to assess heart damage. It's important to note that individuals with certain serious health conditions or those who are pregnant or breastfeeding cannot participate. Overall, this trial seeks to explore a new way to protect the heart during critical moments of care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria: the enrolled subjects must meet all of the following criteria:
• • Aged 18-75 years old (inclusive);
• • Diagnosed with anterior STEMI within 6h of symptom onset: (1) ischemic chest discomfort; (2) electrocardiogram (ECG) with ST elevation ≥0.2 mV in 2 or more contiguous precordial leads (one of which should be V2, V3, or V4);
• • Sign the informed consent form.
• Exclusion Criteria: subjects who meet any one of the following criteria are excluded from the study:
• • Ventricular fibrillation, cardiogenic shock, Killip III-IV grade;
• • Sinus bradycardia (heart rate sustained \<60 beats/min), PR interval\> 240ms or II-III degree atrioventricular block;
• • Continuous systolic blood pressure \<120mmHg;
• • Severe breathing difficulties, aterial blood oxygen saturation \<92%;
• • Thrombolytic therapy has been performed before the first medical contact in the hospital;
• • Consciousness disorder or past cerebrovascular disease;
• • Previous history of myocardial infarction or PCI/CABG treatment;
• • Known severe liver and kidney dysfunction;
• • Known allergy to dexmedetomidine;
• • CMR contraindications: such as claustrophobia, pacemaker or ICD implantation;
• • Pregnant or lactating women;
• • Malignant tumor or expected survival time \<1 year;
• • Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study (eg, poor compliance, inability of the patient to comply with study procedures and/or follow up);
• • Participate in other randomized controlled studies at the same time.